Clinical trial Recruiting at 1 site Interventional Ages 80 and up

Ablation to improve wellbeing and survival in people aged 80 and older with atrial fibrillation

Official title: Wellbeing and Survival Improvement With Event Reduction by Ablation for Atrial Fibrillation in the Very Elderly (WISER-AF)

Run by Beijing Anzhen Hospital · NCT07403760 · Data updated 2026-11-12

This will see if catheter ablation, compared with a sham procedure, improves quality of life over six months for people aged 80 and older with symptomatic atrial fibrillation.

More Atrial Fibrillation (AF) trials

Quick facts

Study typeInterventional
Ages80 Years and up
SexAll
Enrollment136 (estimated)
SponsorBeijing Anzhen Hospital
Academic / other
Locations1 site (Beijing)
StatusRecruiting
StartedJuly 1, 2026
Main results expectedNovember 30, 2028
Study endsDecember 30, 2028
Registry record updatedJuly 6, 2026
Trial IDNCT07403760 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults aged 80 or older with documented paroxysmal or persistent symptomatic AF who can give informed consent and meet procedural safety criteria.

Probably not a fit

Patients with long-standing persistent AF, advanced heart failure (NYHA IV), significant organ failure, left atrial thrombus, prior AF ablation, or other listed exclusion criteria are unlikely to benefit from this protocol.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

WISER-AF is a multicenter, double-blind, sham-controlled randomized trial enrolling 182 symptomatic patients aged 80 or older in Beijing, China. Participants are randomized 1:1 to pulsed field catheter ablation or a sham procedure, with blinding supported by eye masks, headphones, and phrenic nerve stimulation in the sham arm. The primary outcome is change in the SF-36 total score from baseline to six months, and secondary outcomes include AFEQT, Clinical Frailty Scale, LVEF, NT-proBNP, 6-minute walk distance, and cardiovascular events. The design focuses on patient-reported quality of life and functional measures rather than only rhythm outcomes.

Why it matters

Potential benefit: If successful, ablation could meaningfully improve symptoms and overall quality of life for very elderly patients with symptomatic atrial fibrillation.

How similar studies have gone: Previous ablation trials in broader AF populations have shown symptom and quality-of-life benefits, but sham-controlled data specifically in people aged 80 and older are limited, making this approach relatively novel for the very elderly.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Age ≥ 80 years.
2. Documented paroxysmal or persistent atrial fibrillation by ECG or Holter within 6 months prior to enrollment.
3. Symptomatic AF (including palpitations, chest tightness, fatigue, dizziness, blackouts, dyspnea).
4. Voluntary participation and signed informed consent.

Exclusion Criteria:

1. NYHA Class IV heart failure.
2. Acute myocardial infarction, cardiac surgery, or PCI within the past 1 year.
3. Long-standing persistent AF (duration \> 1 year).
4. Left atrial anteroposterior diameter \> 6 cm.
5. History of prior AF ablation.
6. AF secondary to reversible causes (e.g., post-surgery, infection, hyperthyroidism).
7. Severe mitral stenosis.
8. Moderate to severe hepatic failure (Child-Pugh B-C).
9. Renal failure stage 4-5 (eGFR \<30 ml/min/1.73m2) or continuous dialysis.
10. Inability to cooperate due to dementia or severe mental disorder.
11. Presence of left atrial thrombus.
12. Prior Left Atrial Appendage Occlusion (LAAO).
13. Contraindication to anticoagulation.
14. Life expectancy \< 1 year.

Where it's running

  • Beijing Anzhen Hospital, Capital Medical University, Beijing, China
    Beijing, China
    Recruiting

Study contacts

  • Principal investigator: Changsheng Ma, Prof. — Beijing Anzhen Hospital
  • Study coordinator: Liu He, PhD
  • Email: theliu@139.com
  • Phone: +86 13810720787

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.